Literature DB >> 32871826

Prediction of Results of Radiotherapy With Ku70 Expression and an Artificial Neural Network.

Tomokazu Hasegawa1, Masanori Someya2, Masakazu Hori2, Takaaki Tsuchiya2, Yuuki Fukushima2, Yoshihisa Matsumoto3, Koh-Ichi Sakata2.   

Abstract

Background/Aim: Accurate prediction of radiotherapy results is indispensable for the individualized selection of treatment modalities of cancer. We examined the application of the artificial neural network (ANN) model in predicting radiotherapy results using clinical factors and immunohistochemical staining of Ku70 as inputs. Patients and
Methods: We analyzed 79 prostate cancer patients with localized adenocarcinoma treated with radiotherapy between August 2001 and October 2010. We also analyzed 46 hypopharyngeal cancer patients with squamous cell carcinoma treated with radiotherapy between March 2002 and December 2009. The properly trained ANN analysis using a standard feedforward, back-propagation neural network was used to predict the radiotherapy treatment results.
Results: The areas under the receiver-operating characteristic curve (AUC) were 0.939 for patients treated with intensity modulated radiotherapy (IMRT)+androgen deprivation therapy (ADT), 0.803 for IMRT alone, and 0.960 for 3D-conformal radiotherapy (CRT) alone in prostate cancer. Sensitivity and specificity were 85.7% and 90.4% for IMRT+ADT, 75.0% and 88.5% for IMRT alone, and 92.3% and 100% for 3D-CRT alone. The AUC was 0.901 for hypopharyngeal cancer. Sensitivity and specificity were 66.7% and 88.2%, respectively.
Conclusion: We demonstrated a possibility to predict the radiotherapy treatment results in prostate and hypopharyngeal cancer using ANN in combination with Ku70 expression and clinical factors as inputs. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Prediction; artificial neural network; hypopharyngeal cancer; ku70; prostate cancer; radiotherapy

Mesh:

Substances:

Year:  2020        PMID: 32871826      PMCID: PMC7652536          DOI: 10.21873/invivo.12114

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  14 in total

1.  Analysis and results of Ku and XRCC4 expression in hypopharyngeal cancer tissues treated with chemoradiotherapy.

Authors:  Jyunichi Hayashi; Koh-Ichi Sakata; Masanori Someya; Yoshihisa Matsumoto; Masaaki Satoh; Kensei Nakata; Masakazu Hori; Masaru Takagi; Atsushi Kondoh; Tetsuo Himi; Masato Hareyama
Journal:  Oncol Lett       Date:  2012-04-05       Impact factor: 2.967

2.  Expression of genes involved in repair of DNA double-strand breaks in normal and tumor tissues.

Authors:  K Sakata; Y Matsumoto; H Tauchi; M Satoh; A Oouchi; H Nagakura; K Koito; Y Hosoi; N Suzuki; K Komatsu; M Hareyama
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-01-01       Impact factor: 7.038

Review 3.  Nonhomologous DNA end-joining for repair of DNA double-strand breaks.

Authors:  Nicholas R Pannunzio; Go Watanabe; Michael R Lieber
Journal:  J Biol Chem       Date:  2017-12-14       Impact factor: 5.157

4.  Influence of Ku86 and XRCC4 expression in uterine cervical cancer on the response to preoperative radiotherapy.

Authors:  Yu Takada; Masanori Someya; Yoshihisa Matsumoto; Masaaki Satoh; Kensei Nakata; Masakazu Hori; Masato Saito; Naoki Hirokawa; Kunihiko Tateoka; Mizue Teramoto; Tsuyoshi Saito; Tadashi Hasegawa; Koh-Ichi Sakata
Journal:  Med Mol Morphol       Date:  2016-02-11       Impact factor: 2.309

Review 5.  Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications.

Authors:  Sophie E Polo; Stephen P Jackson
Journal:  Genes Dev       Date:  2011-03-01       Impact factor: 11.361

6.  Expression of Ku70 predicts results of radiotherapy in prostate cancer.

Authors:  Tomokazu Hasegawa; Masanori Someya; Masakazu Hori; Yoshihisa Matsumoto; Kensei Nakata; Masanori Nojima; Mio Kitagawa; Takaaki Tsuchiya; Naoya Masumori; Tadashi Hasegawa; Koh-Ichi Sakata
Journal:  Strahlenther Onkol       Date:  2016-07-27       Impact factor: 3.621

7.  Influence of XRCC4 expression in esophageal cancer cells on the response to radiotherapy.

Authors:  Masakazu Hori; Masanori Someya; Yoshihisa Matsumoto; Kensei Nakata; Mio Kitagawa; Tomokazu Hasegawa; Takaaki Tsuchiya; Yuki Fukushima; Toshio Gocho; Yasushi Sato; Hiroyuki Ohnuma; Junji Kato; Shintaro Sugita; Tadashi Hasegawa; Koh-Ichi Sakata
Journal:  Med Mol Morphol       Date:  2016-06-23       Impact factor: 2.309

8.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

Authors:  A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein
Journal:  JAMA       Date:  1998-09-16       Impact factor: 56.272

9.  Early prediction of response to radiotherapy and androgen-deprivation therapy in prostate cancer by repeated functional MRI: a preclinical study.

Authors:  Kathrine Røe; Manish Kakar; Therese Seierstad; Anne H Ree; Dag R Olsen
Journal:  Radiat Oncol       Date:  2011-06-08       Impact factor: 3.481

10.  Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer.

Authors:  Sarah L Kerns; Leila Dorling; Laura Fachal; Søren Bentzen; Paul D P Pharoah; Daniel R Barnes; Antonio Gómez-Caamaño; Ana M Carballo; David P Dearnaley; Paula Peleteiro; Sarah L Gulliford; Emma Hall; Kyriaki Michailidou; Ángel Carracedo; Michael Sia; Richard Stock; Nelson N Stone; Matthew R Sydes; Jonathan P Tyrer; Shahana Ahmed; Matthew Parliament; Harry Ostrer; Barry S Rosenstein; Ana Vega; Neil G Burnet; Alison M Dunning; Gillian C Barnett; Catharine M L West
Journal:  EBioMedicine       Date:  2016-07-20       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.